A Phase II Trial of Regadenoson in Sickle Cell Anemia
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug called Regadenoson (or Lexiscan) to learn whether the drug works in treating a specific disease, in this case Sickle Cell Disease (SCD). "Investigational" means that the drug is being studied. It also means that the FDA has not yet approved the drug for your type of disease.
SCD is an inherited blood disorder that causes the red blood cells to change their shape from a round shape to a half-moon/crescent or sickled shape. People who have SCD have a different type of protein that carries oxygen in their blood (hemoglobin) than people without SCD. This different type of hemoglobin makes the red blood cells change into crescent shape under certain conditions. Sickle-shaped cells are a problem because they often get stuck in the blood vessels blocking the flow of blood, and cause inflammation and injury to important areas in the body.
Regadenoson (trade name Lexiscan) is a drug that may prevent this inflammation and injury caused by the sickle shaped cells. This drug is approved by the FDA to be used as a fast infusion during a heart stress test in people who are unable to exercise enough to put stress on their heart by making the heart beat faster. Regadenoson has been studied as a long infusion at this dose in adults, and no safety issues have been identified (ClinicalTrials.gov Identifier: NCT01085201). This is the first study to look at patient benefit with the long infusion of the drug. This drug has been used in laboratory experiments and information from those other research studies suggests that this drug may help to protect the body from damage caused by sickle-shaped cells in this research study.
In this research study, the investigators are specifically looking to see if Regadenoson is an effective treatment for pain crises and acute chest syndrome in SCD.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
|Official Title:||A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia|
- Determine iNKT cell reduction with Regadenoson vs. Placebo [ Time Frame: 2 years ] [ Designated as safety issue: No ]To determine if infusional regadenoson reduced iNKT cell activation among individuals with SCA and pain or ACS compared to placebo
- Impact of Regadenoson on length of hospital stay [ Time Frame: 2 years ] [ Designated as safety issue: No ]To determine if regadenoson reduces length of hospital stay among individuals admitted with SCA and pain or ACS compared to placebo
- Impact of regadenoson on respiratory symptoms [ Time Frame: 2 years ] [ Designated as safety issue: No ]To determine if regadenoson improved respiratory symptoms among individuals with SCA and pain or ACS compared to placebo
- Impact of regadenoson on opioid use [ Time Frame: 2 years ] [ Designated as safety issue: No ]To determine if regadenoson reduces opioid use among individuals with SCA and pain or ACS compared to placebo
- Impact of regadenoson on level of inflammatory markers [ Time Frame: 2 years ] [ Designated as safety issue: No ]To determine if regadenoson reduces levels of inflammatory markers among individuals with SCA and pain or ACS compared to placebo
|Study Start Date:||May 2013|
|Estimated Study Completion Date:||June 2017|
|Estimated Primary Completion Date:||June 2016 (Final data collection date for primary outcome measure)|
Active Comparator: Regadenoson Arm
1.44 mcg/kg/hour infused over 48 hours
Regadenoson is an A2AR agonist that is a coronary vasodilator. It is chemically described as adenosine, 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]-, monohydrate. Its molecular formula is C15H18N8O5. Regadenoson has an FDA indication for use in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. It has lower affinity for non-A2A adenosine receptor subtypes thought to be associated with some of the adverse effects associated with non-selective adenosine receptor agonists, which increase extracellular adenosine by blocking its uptake into cells. The maximal plasma concentration of regadenoson is achieved within 1 to 4 minutes after injection and parallels the onset of the pharmacodynamic response. Its half-life is approximately 2 to 4 minutes.
Other Name: Lexiscan
Placebo Comparator: Placebo Arm
Placebo infused over 48 hours
This study uses 0.9% Normal Saline (NS) as placebo. This is a sterile sodium chloride solution usually used to replenish fluids and electrolytes. It contains no additives, and is a standard solution used as placebo in clinical trials where the study drug is administration intravenously. NS will be prepared by investigational pharmacy.
Other Name: Regadenoson Placebo, Lexiscan Placebo, 0.9% Normal Saline
Hide Detailed Description
If you are willing to participate in this research study you will be asked to undergo some screening tests and procedures to confirm your eligibility. Many of these tests and procedures are likely to be part of regular sickle cell anemia care and may be done even if it turns out that you do not take part in the research study. If you have had some of these tests and procedures recently, they may or may not have to be repeated. The tests and procedures include: a medical history, physical examination, blood tests, blood or urine pregnancy test (if applicable) and an electrocardiogram. If these tests show that you are eligible to participate in the research study, you will begin the study treatment. If you do not meet the eligibility criteria, you will not be able to participate in the research study. At the time of screening we will also ask you about your pain level.
Because no one knows which of the study options is best, you will be "randomized" into one of the study groups: the "study drug" group, which will receive Regadenoson, or the "control" group, which will receive placebo. Randomization means that you are put into a group by chance. It is like flipping a coin. Neither you nor the research doctor will choose what group you will be in. You will have an equal (50/50) chance of being placed in either group. Neither you nor the research doctor will know what group you are in.
You will be given a study medication and it will contain either Regadenoson or placebo (fluids with no medicine).
You will be given one infusion of the study drug while you are admitted to the hospital for a pain crisis. The study drug will be infused with fluids. You will stay in the hospital for at least 3 days and 2 nights. Your infusion will be 48 hours long, followed by a 6-hour observation period. During your infusion, you will receive standard treatment for your pain crisis. The study drug will be given through a separate part of your body from the infusions that are part of your standard treatment. The study drug will not be available after your participation in the study ends.
Before the infusion: We will place a small tube in your vein called an IV, which will be used only to infuse the study drug. It will not be used for infusions that are part of standard treatment for your pain crisis. During the study drug infusion, standard treatment will be given through a separate IV. We can use your standard treatment IV or a needle to draw blood for the required blood test. If it is hard to draw blood from your veins, we may ask you if you would like to use a peripherally inserted central catheter (PICC line) for your blood draws. A PICC line is a small tube that is placed in a vein in your arm and goes through to a vein in your chest. A chest x-ray is usually done to make sure it is in the right veins. It is your choice to decide whether you would like to use a PICC line. We will record your blood pressure and heart rate every 5-10 minutes, until they have stabilized. We will also ask you about your pain level at the time of your blood test.
During the 48 hour infusion: Your heart rate and the amount of oxygen in your blood will be monitored continuously using a device that fits over your finger. We will take about 2-3 teaspoons of blood at 24 and 48 hours after the beginning of your infusion for tests to try to understand how the drug affects your body. We will ask you about your pain level at the time of each blood test. We will take your blood pressure every 30 minutes for the first 2 hours, then every hour for the next two hours, then every 2 hours for the remainder of the infusion.
A six hour observation period will take place immediately after the infusion. At this time you will undergo the following: your heart rate and the amount of oxygen in your blood will be monitored continuously with a device that fits over your finger. We will take about 5 teaspoons of blood at the end of the period to try to understand how the study drug affects your body. We will ask you about your pain level at the time of your blood test. We will take your blood pressure every 2 hours for the full duration of the observation period.
You may not eat or drink anything that contains caffeine, such as coffee, tea, chocolate or sodas during the infusion and observation periods.
We would like to keep track of your medical condition for 30 days after you receive the study drug. We would like to do this by contacting you on the telephone weekly during the 30 days after your participation to see how you are doing.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01788631
|Contact: David Nathan, MDemail@example.com|
|United States, California|
|Children's Hospital and Research Center at Oakland||Recruiting|
|Oakland, California, United States, 94609|
|Contact: Carolyn Hoppe, MD 510-428-3193 firstname.lastname@example.org|
|Sub-Investigator: Anne Marsh, MD|
|Sub-Investigator: Lynne Neumayr, MD|
|Sub-Investigator: Ward Hagar, MD|
|Sub-Investigator: Elliott Vichinsky, ND|
|United States, Illinois|
|University of Illinois at Chicago||Recruiting|
|Chicago, Illinois, United States, 60612|
|Contact: Victor Gordeuk, MD 312-996-5461 email@example.com|
|Principal Investigator: Victor Gordeuk, MD|
|Sub-Investigator: Robert Molokie, MD|
|Sub-Investigator: Johara Hassan, MD|
|Sub-Investigator: Michel Gowhari, DO|
|Sub-Investigator: Lewis Hsu, MD|
|Sub-Investigator: Santosh Saraf, MD|
|Sub-Investigator: Chaher Alhandalous, MD|
|United States, Maryland|
|Johns Hopkins University||Terminated|
|Baltimore, Maryland, United States, 21205|
|United States, Massachusetts|
|Boston Children's Hospital||Recruiting|
|Boston, Massachusetts, United States, 02215|
|Contact: Matthew Heeney, MD 617-355-7700 firstname.lastname@example.org|
|Principal Investigator: Matthew Heeney, MD|
|Sub-Investigator: Ellis Neufeld, MD, PhD|
|Sub-Investigator: Venee Tubman, MD|
|Brigham and Women's Hospital||Recruiting|
|Boston, Massachusetts, United States, 02215|
|Contact: Maureen Okam, MD, MPH 617-732-5048 email@example.com|
|Principal Investigator: Maureen Okam, MD, MPH|
|Sub-Investigator: Ronald McCaffrey, MD|
|Sub-Investigator: Nancy Berliner, MD|
|Sub-Investigator: Elyse Mandell, NP|
|Dana-Farber Cancer Institute||Active, not recruiting|
|Boston, Massachusetts, United States, 02215|
|United States, Michigan|
|Wayne State University/Karmanos Cancer Institute||Terminated|
|Detroit, Michigan, United States, 48201|
|United States, Missouri|
|Washington University in St. Louis||Recruiting|
|St. Louis, Missouri, United States, 63110|
|Contact: Elaine Majerus, MD, PhD 312-362-8866 EMajerus@dom.wustl.edu|
|Principal Investigator: Elaine Majerus, MD, PhD|
|United States, North Carolina|
|Durham, North Carolina, United States, 27705|
|United States, Ohio|
|Cincinnati Children's Hospital Medical Center||Terminated|
|Cincinnati, Ohio, United States, 45229|
|United States, Texas|
|Baylor College of Medicine||Recruiting|
|Houston, Texas, United States, 77030|
|Contact: Alex George, MD 832-822-4583 firstname.lastname@example.org|
|Sub-Investigator: Gladstone Airewele, MD|
|Sub-Investigator: Vivien Sheehan, MD|
|Sub-Investigator: Corrie E Chumpitazi, MD|
|Sub-Investigator: Mary Louise Vaughan, MS|
|Sub-Investigator: Susan Edwinna Kirk, MS|
|Sub-Investigator: Deborah Lynn Shardy, MD, PhD|
|Sub-Investigator: Donald Mahoney, Jr., MD|
|Sub-Investigator: Amber Meshell Yates, MD|
|Sub-Investigator: Victor Mario Gonzales, MD|
|Sub-Investigator: Bogdan Dinu, MD|
|United States, Wisconsin|
|Medical College of Wisconsin||Recruiting|
|Milwaukee, Wisconsin, United States, 53226|
|Contact: Joshua Field, MD, MS 414-937-3848 Joshua.email@example.com|
|Principal Investigator: Joshua Field, MD, MS|
|Sub-Investigator: Patrick Foy, MD|
|Sub-Investigator: Kathryn Koch, NP|
|Sub-Investigator: Meenu Singh, MD|
|Principal Investigator:||David Nathan, MD||Dana-Farber Cancer Institute|